Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Akouos, Inc. (AKUS)

13.2   0.03 (0.23%) 11-25 13:00
Open: 13.17 Pre. Close: 13.17
High: 13.21 Low: 13.16
Volume: 593,915 Market Cap: 488(M)

Technical analysis

as of: 2022-11-28 8:46:10 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.61     One year: 15.88
Support: Support1: 13    Support2: 10.81
Resistance: Resistance1: 13.37    Resistance2: 13.6
Pivot: 13.3
Moving Average: MA(5): 13.21     MA(20): 13.26
MA(100): 6.81     MA(250): 5.79
MACD: MACD(12,26): 0.7     Signal(9): 1
Stochastic oscillator: %K(14,3): 29.4     %D(3): 32.7
RSI: RSI(14): 70.8
52-week: High: 13.6  Low: 2.31
Average Vol(K): 3-Month: 605 (K)  10-Days: 404 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AKUS ] has closed above bottom band by 26.1%. Bollinger Bands are 84.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 13.22 - 13.27 13.27 - 13.33
Low: 13.02 - 13.07 13.07 - 13.14
Close: 13.1 - 13.19 13.19 - 13.29

Company Description

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headline News

Sun, 27 Nov 2022
A'o Aku; A'o Mai: What I Learn, I Teach | The Molokai Dispatch - Molokai Dispatch

Thu, 17 Nov 2022
SHAREHOLDER ALERT: Weiss Law Reminds LBC, AERC, AKUS, and ABMD Shareholders About Its Ongoing Investigations - PR Newswire

Thu, 17 Nov 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, AKUS, PEBO - Orthofix Medical (NASDAQ:OFIX - Benzinga

Wed, 16 Nov 2022
INVESTOR ALERT: The M&A Class Action Firm Continues Investigating the Merger – AKUS, JVA, SMBC - Coffee H - Benzinga

Tue, 15 Nov 2022
SHAREHOLDER ALERT: Weiss Law Reminds USER, CLR, AKUS, and LFG Shareholders About Its Ongoing Investigations - Marketscreener.com

Fri, 11 Nov 2022
SHAREHOLDER ALERT: Weiss Law Reminds RCOR, BTRS, AERC, and AKUS Shareholders About Its Ongoing Investigations - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 37 (M)
Shares Float 19 (M)
% Held by Insiders 1.1 (%)
% Held by Institutions 104.8 (%)
Shares Short 828 (K)
Shares Short P.Month 2,280 (K)

Stock Financials

EPS -2.83
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.9
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -22.3
Return on Equity (ttm) -42.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.45
Qtrly Earnings Growth 0
Operating Cash Flow -74 (M)
Levered Free Cash Flow -60 (M)

Stock Valuations

PE Ratio -4.67
PEG Ratio -0.2
Price to Book value 2.69
Price to Sales 0
Price to Cash Flow -6.59

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.